Design and rationale of the MyHeartMate study: a randomised controlled trial of a game-based app to promote behaviour change in patients with cardiovascular disease by unknown
1Gallagher R, et al. BMJ Open 2019;9:e024269. doi:10.1136/bmjopen-2018-024269
Open access 
Design and rationale of the 
MyHeartMate study: a randomised 
controlled trial of a game-based app to 
promote behaviour change in patients 
with cardiovascular disease
Robyn Gallagher,1 Clara Chow,2 Helen Parker,1,3 Lis Neubeck,4 David Celermajer,5,6 
Julie Redfern,7 Geoffrey Tofler,5,8 Thomas Buckley,1 Tracy Schumacher,9 
Cate Ferry,10 Alexandra Whitley,11 Lily Chen,12 Gemma Figtree5,13
To cite: Gallagher R, Chow C, 
Parker H, et al.  Design and 
rationale of the MyHeartMate 
study: a randomised controlled 
trial of a game-based app to 
promote behaviour change in 
patients with cardiovascular 
disease. BMJ Open 
2019;9:e024269. doi:10.1136/
bmjopen-2018-024269
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
024269).
Received 18 May 2018
Revised 29 November 2018
Accepted 30 January 2019
For numbered affiliations see 
end of article.
Correspondence to
Professor Robyn Gallagher;  
 robyn. gallagher@ sydney. edu. au
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Recurrence of cardiac events is common 
after a first event, leading to hospitalisations and increased 
health burden. Patients have difficulties achieving the 
lifestyle changes required for secondary prevention and 
access to secondary prevention programs is limited. 
This study aims to evaluate the impact of a game-based 
mobile app, MyHeartMate, which is designed to motivate 
engagement in secondary prevention behaviours for 
cardiovascular risk factors.
Methods and analysis The MyHeartMate study is a 
randomised controlled trial with 6-month follow-up and 
blinded assessment of the primary outcome. Participants 
(n=394) with coronary heart disease will be recruited from 
hospitals in metropolitan Sydney and randomly allocated 
to standard care or the MyHeartMate app intervention. The 
intervention group will receive the app, which uses game 
techniques to promote engagement and lifestyle behaviour 
change for secondary prevention. The primary outcome 
is difference between the groups in physical activity 
(metabolic equivalent of task minutes/week) at 6 months. 
Secondary outcomes include change in low-density 
lipoprotein cholesterol, systolic blood pressure, medication 
adherence, body mass index, waist circumference, 
mood and dietary changes at 6 months. Data on app 
engagement, and patient perspectives of usability and 
acceptability, will also be analysed.
Ethics and dissemination The study has received ethics 
approval from Northern Sydney Local Health District 
Human Research Ethics Committee. The study findings 
will be disseminated via peer-reviewed publications 
and presentation at international scientific meetings/
conferences.
trial registration number ACTRN12617000869370; Pre-
results.
IntroduCtIon
Globally, coronary heart disease (CHD) is a 
leading cause of death.1 Recurrent events are 
common, leading to hospitalisations and an 
increased burden on the individual and the 
health system.2 Secondary prevention has 
a key role in limiting recurrence; however, 
patients have difficulty achieving the life-
style changes required, including increasing 
levels of physical activity, and medication 
adherence.3 Data from registries indicate that 
6 months post myocardial infarction (MI) 
only 68% of patients are taking all cardiopro-
tective medications prescribed,4 and <60% 
are engaging in sufficient exercise.5 When 
patients do engage in secondary prevention, 
with the support of effective programmes 
they can reduce cardiovascular mortality and 
hospital admission.6 7 Despite these benefits, 
patients often do not participate in these 
programmes; only one-third of MI patients 
attend cardiac rehabilitation (CR).8 The 
limited times and location of conventional 
strengths and limitations of this study
 ► The study evaluates a novel game-based mobile app 
strategy of accessing secondary prevention support 
for reducing cardiovascular disease (CVD) risk fac-
tors in patients at high risk of further CVD events.
 ► A standalone freely available mobile app on iPhone 
Operating System  and Android platforms is being 
tested on coronary heart disease (CHD) patients.
 ► This study will be the first to provide rigorous data 
on effectiveness of a gamification approach through 
a randomised controlled trial in CHD patients.
 ► This initial study is being conducted in a single city 
(Sydney, Australia) and in English, which may lim-
it potential generalisability to other countries and 
languages. Contamination of the control group is 
possible as participants may choose to use the app. 
Blinding of the primary outcome is enabled by auto-
matic upload of activity data; however, other assess-
ments are non-blinded.
 o
n
 12 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024269 on 14 May 2019. Downloaded from 
2 Gallagher R, et al. BMJ Open 2019;9:e024269. doi:10.1136/bmjopen-2018-024269
Open access 
CR mean that many patients cannot attend due to travel 
requirements, conflict with work and carer demands and 
group-based delivery not being a personal preference.6 8 
Therefore, new strategies are needed to enable access to 
secondary prevention support.
Advances in technology, particularly through the 
growth of smartphone use, provide an opportunity to 
overcome barriers to secondary prevention access. The 
adoption of smartphones has been widespread in devel-
oped countries, and adoption by seniors shows the fastest 
increase.9 A recent study of 285 cardiac patients reported 
that 70.9% used mobile phones, and 54.6% were using 
technology for health purposes.10 Furthermore, 68% of 
cardiac patients were interested in receiving CR support 
via their mobile phone.11 Mobile technology offers 
immediate access to information, and the potential to 
personalise secondary prevention support and incentivise 
behaviour change. In line with the increased availability 
and affordability of smartphones, there has been huge 
expansion in availability of mobile health apps.
Mobile apps show promise for improving CHD risk 
factor and lifestyle behaviours, although the evidence 
is still accumulating for CHD-specific apps.12 A recent 
systematic review identified 10 standalone apps for adults 
who had evidence supporting their use in CHD.13 Benefits 
were demonstrated for risk factors including blood pres-
sure, body mass index (BMI), cholesterol and exercise 
capacity, as well as reduction in hospitalisation rates.13 The 
reviewers noted that sustained engagement with the app 
was crucial for benefits to be achieved, and also reported 
app features participants preferred. Goal setting, recogni-
tion of achievements, challenges, data entry, team-based 
competition and other game-related design techniques 
were identified as elements most preferred by app users.
Game-design techniques (gamification) harness innate 
human desires for competition and social connection 
and incorporate multiple behaviour change techniques.14 
Game techniques include undertaking challenges/quests 
that are increasingly difficult, and incorporating rewards 
and the opportunity for comparison with other players 
at each level.15 These game strategies are congruent with 
social cognitive theory-based techniques for the develop-
ment of self-efficacy.16 Game attributes, both alone and 
in combination, are evident in many well-established 
health behaviour change interventions, regardless of 
whether they have that label.17 18 Despite identifying 64 
health behaviour apps in the Apple and Google Play 
stores in a comprehensive systematic review, the reviewers 
concluded that few use game techniques.18 Standalone 
game-based mobile apps designed specifically for CHD 
patients are even rarer.
Game strategies accessed through mobile tablets offer 
insights. Two games, one for heart failure patients, Heart 
Health,19 and another for CHD patients and their families, 
The Heart Game, have pilot studies which report high levels 
of engagement20 and benefits for self-care behaviours. 
Interest and enjoyment are critical to the feasibility of 
game-based apps, and 67% of older cardiac patients are 
reported to be interested in game-based CR (67%).11 
Both studies reported stronger interest in younger 
patients.19 20 To date, there is very limited research testing 
of game-based apps for CHD patients; therefore, the 
primary objective of this study is to determine the impact 
of a game-based app on physical activity. EUROASPIRE 
IV demonstrated that having little or no physical activity 
was the most prevalent modifiable risk factor in CHD 
patients.21 Given the well-established dose–response 
benefits for mortality by increasing the volume and inten-
sity of habitual physical activity in CHD patients a focus 
on physical activity outcomes is justified.22 The secondary 
objective is to determine the impact of the app on CHD 
risk factors, lifestyle-based risk factor behaviours and 
psychological status. An additional objective is to deter-
mine level of engagement, acceptability of the app in 
practice and identification of game strategies participants 
find useful.
MEthods And AnAlysIs
study design
The MyHeartMate study is a parallel group, two-arm, 
superiority randomised controlled trial with 1:1 allo-
cation ratio and 6-month follow-up. The study will be 
conducted in three university teaching hospitals in 
Sydney, Australia serving ethnically, culturally and socio-
economically diverse populations. Participants with CHD 
will be randomly allocated to either the control group for 
standard care or to the intervention group, who will be 
provided the MyHeartMate app to engage with to receive 
support for secondary prevention behaviours (figure 1). 
Outcomes will be assessed using objective measures at 
6 months in-person at the hospital site. Recruitment to 
the study began in December 2017 and will be concluded 
in December 2019.
randomisation
Participants will be randomly allocated to either the 
control group or intervention group (1:1) via a comput-
erised randomisation schedule ( www. randomization. 
com). After enrolment, recruiting research staff will call 
the study coordinator who will first provide the alloca-
tion, and then register the participant. Participants will 
be asked not to discuss their group allocation or the study 
app with any other heart patients except with immediate 
family during the study to avoid contamination. The 
intervention is self-delivered and the primary outcome 
data automatically uploaded from the Fitbit tracker to the 
database. However, staff undertaking all other outcome 
assessments are not blinded.
study population
Eligible patients will be those presenting to hospital for 
management of CHD. Patients will be eligible if they have 
(1) presented with acute coronary syndrome and/or have 
documented CHD on angiography (>50% stenosis in at 
least one epicardial vessel), (2) own a smartphone and 
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self-report using apps most days of the week, (3) provide 
informed consent and (4) have sufficient English profi-
ciency to adequately/successfully interact with the app. 
Exclusions will apply to candidates who have visual, fine 
motor or diagnosed neurocognitive disorder which limits 
engagement with the app. Research staff will approach, 
screen and recruit patients at each study site. A screening 
log will be used to identify ineligible patients or those who 
refuse and include age, gender and reasons for refusal.
Interventions
The control group will receive standard care for CHD, 
which will include medication prescription and risk factor 
reduction advice according to their medical provider’s 
determination and the Heart Foundation, Managing My 
Heart Health information booklet. Control group partic-
ipants are requested to not access the app during the 
study, but may do so at study end. The MyHeartMate group 
(intervention) will receive standard care, plus access to 
the MyHeartMate app, a brief (5 min) in-person informa-
tion provision for participants to upload and log in to the 
app for the first time and location of the freely available 
brief instructional video on the app goals and optimal 
use of the app functions. The MyHeartMate group will be 
encouraged to use the app at least twice weekly within 
the 6-month follow-up, but may choose how they do this, 
including returning to use the app after a period of not 
using it. Multiple methods are used within the app design 
to promote participant’s engagement with the app and 
with secondary prevention behaviours (online supple-
mentary table 1). The app has a focus on promoting 
regular physical activity but also encourages participants 
to take their medications as prescribed and engage with 
their treating doctors, eat a healthy diet, manage their 
weight and lipid levels, manage stress and quit smoking 
if applicable.
All participants will be provided with the research staff 
contact details and will be contacted once by these staff 
by phone during the follow-up period to check contact 
details and book the follow-up appointment. If the 
MyHeartMate backend log indicates that a participant has 
not engaged with the app in the 2 days following recruit-
ment a single phone call will be made to the participant 
for troubleshooting. Participants may withdraw at any 
time by contacting the researchers.
MyHeartMate app intervention development
The MyHeartMate smartphone app is designed to engage 
CHD patients in secondary prevention behaviours iden-
tified in national guidelines.23 The app is built on an 
award-winning behaviour change platform (Habitat the 
Game) developed by Elevator Entertainment and has 
been developed through an iterative process involving 
experts and patients. The central feature is a heart avatar, 
Figure 1 Study design and participant flow through study. CV, cardiovascular. 
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which requires the same care as the CHD patient, namely 
healthy food, exercise, mental health/stress-reduction 
time and cardiac-relevant medications. Multiple game 
strategies are incorporated that are known to harness 
innate goal-driven, competition and playful human moti-
vations to promote engagement in healthy behaviours 
(online supplementary table 1).15 Specifically, feedback 
and monitoring, comparison of behaviour, reward and 
threat, associations, self-belief and goals and planning 
are incorporated as classified in Michie et al behaviour 
change taxonomy.17 Improving participant’s self-efficacy 
for lifestyle change is a key goal so specific techniques 
derived from social cognitive theory proven to be effec-
tive are central and include mastery of graded behaviours 
such as exercise, understanding responses to behaviours 
and persuasion.24
The user earns virtual coins to purchase care items for 
their heart avatar by completing short-term and long-term 
health-related challenges. These are real-world secondary 
prevention tasks including healthy eating, physical 
activity, achieving a healthy weight, activities to reduce 
blood pressure and control blood cholesterol, medica-
tion adherence, quitting smoking (where relevant) and 
engaging in activities to enhance psychological well-
being. A bank of 100 challenges were developed for this 
purpose based on national guidelines and then reviewed 
by an expert multidisciplinary panel, which included 
leading clinicians (cardiologists, nurses, a physiothera-
pist, dietitians, exercise scientist) as well as academics 
and researchers. Coins can also be earned by completing 
real-world missions, health quizzes and playing games, 
which increase in difficulty as the user progresses. Users 
can compete with others including their friends via the 
community leader board. Performance can be assessed 
by entering and tracking their own health data over time 
through graphs.
The heart avatar appearance and animation was devel-
oped in consultation with a purposive sample of older 
people who had CHD and aims to personalise the effects 
of health behaviours undertaken25 (figure 2). The beta 
version of the app was tested and evaluated by CR partic-
ipants (n=18) who were requested to interact with the 
app most days over 2 weeks. Feedback on understanding 
and usefulness was collected during five focus groups. 
Changes made based on this feedback included an intro-
duction to the app and game purpose, acknowledging the 
serious nature of CHD and the serious intent of the game 
(YouTube video tutorials and a Facebook page). Other 
changes included brief pop-up instructions for each part 
of the app when it is first used, weekly push notifications 
to use the game if not being used for 7 days (ceasing at 
21 days), open availability on the app store for family and 
friends, easier tracking and data entry through syncing 
with a wearable tracker (FitBit Flex), easy-to-read graphs 
on their data, easy log-in and forgotten password tab and 
visual reminder of scrolling.
The app is standalone and completely automated, with 
the exception of congratulatory emails. These emails are 
written by research staff using a template when the app 
automatically generates an email to the staff that a partic-
ipant has reached a key goal for the first time such as 
‘My blood pressure is less than 130/90 for the first time’, 
or ‘My weight is in the healthy range for the first time’. 
These are more tangible rewards for using the app, and 
are expected to result in improved user perception of the 
app and increased likelihood of continuing to use the 
app and continuing to record user achievement of real-
world missions in the app.
study outcomes
The primary outcome of the study is improvement 
(difference between intervention and control groups) in 
physical activity in terms of metabolic equivalent of task 
minutes/week (MET-min/week), as measured by the 
wearable activity tracker FitBit Flex.26 Physical activity has 
been selected given the strong association with survival 
in CHD patients.27 Automated upload ensures blinding 
of assessment. Secondary outcomes include improvement 
(difference between intervention and control groups) in 
physical activity components, lipid levels, BMI and waist 
circumference, blood pressure, dietary intake, psycholog-
ical state, medication adherence, cardiac events including 
MI, death or any hospital presentation or admission, 
participation in CR or other secondary prevention strat-
egies and visits to healthcare providers. Outcomes and 
measures are provided in detail in online supplementary 
Figure 2 MyHeartMate avatar.
 o
n
 12 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024269 on 14 May 2019. Downloaded from 
5Gallagher R, et al. BMJ Open 2019;9:e024269. doi:10.1136/bmjopen-2018-024269
Open access
table 2.28–30 Additional outcomes assessed include 
engagement with the MyHeartMate app. The combined/
absolute number of modifiable risk factors above/below 
target thresholds will be calculated. Participants will be 
assessed during an in-person interview by research staff at 
6 months. Additional data collected will be used to char-
acterise the sample, enable subgroup analyses and insight 
into app uptake. These data include age, gender, marital 
status, employment, ethnicity, home language, education 
level and residential suburb.
Process measures
Level of competence with technology will be assessed at 
baseline using two questions on confidence,10 and the 
e-Health Literacy Scale with eight items.31 Engagement 
with the app will be assessed using the app log file for 
number and type of challenges and quizzes under-
taken, total coins earned and completion of profile data. 
Communication by staff for the congratulatory emails 
will be timed and noted in detailed logs. Assessment of 
contamination to the control group will be undertaken 
by scanning the user registry log of the app.
MyHeartMate acceptability and feasibility will be assessed 
through a questionnaire after the 6-month follow-up 
assessment. Items will include acceptability of the game 
format, reminders, identification of game aspects partic-
ipants liked or disliked, their perceptions of the utility 
of game aspects for their cardiac health, use of tutorial 
videos and suggestions for improvement.
Potential facilitators and barriers to the effectiveness 
of the app will be assessed through four focus groups 
of a subsample of 20–25 participants of intervention 
group participants. Recruitment will occur on the basis 
of ensuring diversity in gender, age and geography. 
Sampling will occur until theoretical saturation (no new 
themes emerge), which is expected to occur at 20–25 
interviews.32 Focus groups will be facilitated by research 
staff independent of the recruiting and outcomes assess-
ment staff. Focus groups will address individual app use, 
likes and dislikes, the effectiveness of different game 
aspects for behaviour change, including monitoring and 
tracking and participation in the community leaderboard, 
the appropriateness of the visual elements, the ease and 
understanding of the app features, language and content, 
and any discussion or sharing of the app with others. All 
interviews will be audiorecorded and transcribed, and 
entered into NVIVO V.7 for analyses. An iterative process 
of reading, identifying themes and checking will be used 
for analyses.32
Patient and public involvement
Cardiac patients’ preferences in relation to using mobile 
apps and activity trackers10 were assessed and directly 
informed app development and design. Volunteers (past 
patients) who support CR in Northern Sydney Local 
Health District also provided feedback on the app inter-
face and avatar appearance. Patients were not involved 
in designing the study. Study participants will receive 
a summary of the study results by email at the study 
conclusion.
statistical considerations
Study data will be analysed using intention-to-treat 
principles. The primary analysis will use analysis of 
covariance with baseline values of the study outcome 
measures used as covariates where appropriate for 
continuous variables. This method will be used for the 
primary outcome of MET-min/week and for secondary 
outcomes of mean daily step count and minutes of 
moderate-vigorous exercise, lipid levels, BMI, waist, 
blood pressure, anxiety and depression at 6 months. 
Categorical variables (smoking, achieving risk factors at 
guideline level) will be compared using χ2 tests for cate-
gorical variables. Additionally, relative risks, with 95% 
CIs will be calculated to compare groups using log-bi-
nomial regression.
Sample size has been calculated based on detecting a 
difference of 345 (SD 114) MET-min/week between the 
control and intervention groups based on the TEXT ME 
secondary prevention study in a similar population.29 
Assuming r=0.5 correlation between baseline and final 
outcome measurement with alpha=0.05 and power (1–
beta)=0.95, the required sample size is 164 patients per 
group, assuming a 1:1 allocation ratio for control and 
intervention groups. The total sample size, of 328 with 
an additional allowance of 20% loss to follow-up, is 394 
patients.
EthICs And dIssEMInAtIon
The study will be administered by the University of 
Sydney. A research management committee including 
experts in large-scale trials, CHD treatment, qualita-
tive analyses and translation into practice, will be over-
seeing the design and conduct of the research. The 
study is guided by, and adheres to, the National Health 
and Medical Research Council of Australia ethical 
guidelines for human research. All participants will 
have provided written and informed consent, verified 
by a witness. No reimbursement is provided to study 
participants. The study findings will be disseminated via 
publication of peer-reviewed manuscripts, and presen-
tations at international conferences, as well as through 
media publications. It is anticipated that the findings 
will help to inform future developments in the delivery 
of secondary prevention of CHD.
strengths and limitations
A strength of the study is that recruitment is from 
ethnically, culturally and socioeconomically diverse 
sites; however, external generalisability is limited by the 
English language requirements and single city context. 
An additional strength is the use of multiple objectively 
assessed outcomes, including physical activity; however, 
several outcomes are self-report, which has inherent 
risk of bias, for example, from poor recall and social 
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desirability, and these data are collected by non-blinded 
staff. Contamination of the control group is possible as 
participants may choose to use the app.
ConClusIons
This study will evaluate a novel strategy of accessing 
secondary prevention support for reducing CHD risk 
factors in patients at high risk of further CHD events. No 
published study has evaluated a game-based mobile app 
designed specifically for CHD patients in a randomised 
controlled trial; therefore, this study will be the first to 
provide rigorous data on effectiveness of this approach in 
CHD patients.
Smartphone technology has the potential to address 
many of the obstacles CHD patients face in accessing 
secondary prevention programmes. However, strategies 
are not clearly articulated in study methods or engage-
ment with individual components is poorly quantified. 
The study will address these deficits and explore rela-
tionships between strategies and outcomes. Furthermore, 
the app may be used in conjunction with evidence-based 
programmes such as CR to provide additional support 
for behaviour change and scaled-up for large numbers of 
CHD patients.
The MyHeartMate study will test the efficacy of a game-
based smartphone app to improve CHD risk factors 
and lifestyle behaviours in patients who have CHD. The 
MyHeartMate app provides a potential platform for smart-
phone apps for secondary prevention in patients with 
other chronic diseases, and, as an openly available app, 
the potential for standalone access to large numbers of 
people affected by CHD and their families.
Author affiliations
1Sydney Nursing School, University of Sydney, Sydney, New South Wales, Australia
2Faculty of Medicine and Health, University of Sydney, Camperdown, New South 
Wales, Australia
3Faculty of Health Sciences, University of Sydney, Sydney, New South Wales, 
Australia
4Health and Social Care, Edinburgh Napier University, Edinburgh, UK
5Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, 
Australia
6Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, New South 
Wales, Australia
7Westmead Clinical School, University of Sydney, Sydney, New South Wales, 
Australia
8Department of Cardiology, Royal North Shore Hospital, St Leonards, New South 
Wales, Australia
9Faculty of Health and Medicine, University of Newcastle, Newcastle, New South 
Wales, Australia
10Clinical Programs, Heart Foundation, Deakin, Australian Capital Territory, Australia
11Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia
12Department of Cardiology, Westmead Hospital, Westmead, New South Wales, 
Australia
13Cardiothoracic and Vascular Health, Kolling Institute of Medical Research, Saint 
Leonards, New South Wales, Australia
Acknowledgements The authors wish to acknowledge Kylee Ingram and Elevator 
Entertainment for their contribution to development of the MyHeartMate app. The 
authors also wish to acknowledge the invaluable assistance of volunteers working 
in cardiac rehabilitation services of Northern Sydney Local Health District.
Contributors LN, GF and RG conceived the original concept of the study. RG, GF, 
CC, HP, LN, DC, JR, GT, TB, TS, CF, AW and LC contributed to the design of the study 
and are involved in the study implementation. RG, GF, CC, HP, JR, GT, TB, TS and 
CF wrote the content for the MyHeartMate app. RG prepared the first draft of the 
manuscript. RG, CC, HP, LN, DC, JR, GT, TB, TS, CF, AW, LC and GF were involved in 
the critical revision of the manuscript for important intellectual content and final 
approval of the manuscript.
Funding This work was supported by a Charles Perkins Centre Michael Hintze 
Incubator Fund, a Heart Foundation Vanguard Grant (VG 1013632) and a Ramsay 
Research Training Fund Grant. The funders have no influence on study design, data 
collection or the decision to submit reports for publication. GF is supported by an 
NHMRC Practitioner Fellowship. 
Competing interests None declared. 
Patient consent for publication Not required.
Ethics approval The study has received Human Research Ethics approval from 
Northern Sydney Local Health District and governance approval from all recruitment 
sites. 
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. World Health Organisation. WHO fact sheet no. 317: World Health 
Organisation. 2011 http://www. who. int/ en/ news- room/ fact- sheets/ 
detail/ cardiovascular- diseases-( cvds) (Accessed 15 Mar 2018).
 2. Atkins ER, Geelhoed EA, Knuiman M, et al. One third of hospital 
costs for atherothrombotic disease are attributable to readmissions: 
a linked data analysis. BMC Health Serv Res 2014;14:338.
 3. Shore S, Jones PG, Maddox TM, et al. Longitudinal persistence 
with secondary prevention therapies relative to patient risk after 
myocardial infarction. Heart 2015;101:800–7.
 4. Brieger D, Chow C, Gullick J, et al. Improving patient adherence to 
secondary prevention medications 6 months after an acute coronary 
syndrome: observational cohort study. Intern Med J 2018;48:541–9.
 5. Urbinati S, Olivari Z, Gonzini L, et al. Secondary prevention after 
acute myocardial infarction: drug adherence, treatment goals, and 
predictors of health lifestyle habits. The BLITZ-4 Registry. Eur J Prev 
Cardiol 2015;22:1548–56.
 6. Clark AM, Hartling L, Vandermeer B, et al. Meta-analysis: secondary 
prevention programs for patients with coronary artery disease. Ann 
Intern Med 2005;143:659–72.
 7. Anderson L, Thompson DR, Oldridge N, et al. Exercise-based 
cardiac rehabilitation for coronary heart disease. Cochrane Database 
Syst Rev 2016:Cd001800.
 8. Peters AE, Keeley EC. Trends and Predictors of Participation in 
Cardiac Rehabilitation Following Acute Myocardial Infarction: Data 
From the Behavioral Risk Factor Surveillance System. J Am Heart 
Assoc 2017;7:e007664.
 9. Deloitte. Australian media and digital preferences. 4th edn. Deloitte, 
2015.
 10. Gallagher R, Roach K, Sadler L, et al. Mobile technology use across 
age groups in patients eligible for cardiac rehabilitation: survey study. 
JMIR Mhealth Uhealth 2017;5:e161.
 11. Buys R, Claes J, Walsh D, et al. Cardiac patients show high interest 
in technology enabled cardiovascular rehabilitation. BMC Med Inform 
Decis Mak 2016;16:95.
 12. Neubeck L, Lowres N, Benjamin EJ, et al. The mobile revolution--
using smartphone apps to prevent cardiovascular disease. Nat Rev 
Cardiol 2015;12:350–60.
 13. Coorey GM, Neubeck L, Mulley J, et al. Effectiveness, acceptability 
and usefulness of mobile applications for cardiovascular disease 
self-management: Systematic review with meta-synthesis of 
quantitative and qualitative data. Eur J Prev Cardiol 2018;25:505–21.
 14. King D, Greaves F, Exeter C, et al. 'Gamification': influencing health 
behaviours with games. J R Soc Med 2013;106:76–8.
 15. Cugelman B. Gamification: what it is and why it matters to digital 
health behavior change developers. JMIR Serious Games 2013;1:e3.
 16. Bandura A. Social foundations of thought and action. A Social 
Cognitive Theory 1986.
 o
n
 12 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024269 on 14 May 2019. Downloaded from 
7Gallagher R, et al. BMJ Open 2019;9:e024269. doi:10.1136/bmjopen-2018-024269
Open access
 17. Michie S, Richardson M, Johnston M, et al. The behavior change 
technique taxonomy (v1) of 93 hierarchically clustered techniques: 
building an international consensus for the reporting of behavior 
change interventions. Ann Behav Med 2013;46:81–95.
 18. Edwards EA, Lumsden J, Rivas C, et al. Gamification for health 
promotion: systematic review of behaviour change techniques in 
smartphone apps. BMJ Open 2016;6:e012447.
 19. Radhakrishnan K, Toprac P, O'Hair M, et al. Interactive Digital 
e-Health Game for Heart Failure Self-Management: A Feasibility 
Study. Games Health J 2016;5:366–74.
 20. Dithmer M, Rasmussen JO, Grönvall E, et al. "The Heart Game": 
using gamification as part of a telerehabilitation program for heart 
patients. Games Health J 2016;5:27–33.
 21. Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE 
Investigators. EUROASPIRE IV: A European Society of Cardiology 
survey on the lifestyle, risk factor and therapeutic management of 
coronary patients from 24 European countries. Eur J Prev Cardiol 
2016;23:636–48.
 22. Stewart RAH, Held C, Hadziosmanovic N, et al. STABILITY 
Investigators. Physical Activity and Mortality in Patients 
With Stable Coronary Heart Disease. J Am Coll Cardiol 
2017;70:1689–700.
 23. National Heart Foundation of Australia, Cardiac Society of Australia 
and New Zealand. Reducing risk in heart disease: an expert guide to 
clinical practice for secondary prevention of coronary heart disease. 
Melbourne: National Heart Foundation of Australia, 2012.
 24. Olander EK, Fletcher H, Williams S, et al. What are the most effective 
techniques in changing obese individuals' physical activity self-
efficacy and behaviour: a systematic review and meta-analysis. Int J 
Behav Nutr Phys Act 2013;10:29.
 25. Morie J, Haynes E, Chance E, et al. Virtual Worlds and Avatars as 
the New Frontier of Telehealth Care. In: Wiederhold BK, Riva G, eds. 
Annual Review of Cybertherapy and Telemedicine, 2012:27–32.
 26. Alharbi M, Bauman A, Neubeck L, et al. Validation of Fitbit-Flex as 
a measure of free-living physical activity in a community-based 
phase III cardiac rehabilitation population. Eur J Prev Cardiol 
2016;23:1476–85.
 27. Loprinzi PD, Addoh O. The effects of free-living physical activity 
on mortality after coronary artery disease diagnosis. Clin Cardiol 
2016;39:165–9.
 28. World Health Organisation. Global Physical Activity Questionnaire 
(GPAQ). Analysis Guide Geneva: World Health Organisation, 2013.
 29. Chow CK, Redfern J, Hillis GS, et al. Effect of lifestyle-focused text 
messaging on risk factor modification in patients with coronary heart 
disease: a randomized clinical trial. JAMA 2015;314:1255–63.
 30. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. 
Acta Psychiatr Scand 1983;67:361–70.
 31. Norman CD, Skinner HA. eHEALS: The eHealth Literacy Scale. J 
Med Internet Res 2006;8:e27.
 32. Brod M, Tesler LE, Christensen TL. Qualitative research and content 
validity: developing best practices based on science and experience. 
Qual Life Res 2009;18:1263–78.
 o
n
 12 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024269 on 14 May 2019. Downloaded from 
